Founder, Chief Executive Officer and Chairman
Triton Thalassic Technologies, Inc.

Barry Ressler, Founder, Chief Executive Officer and Chairman of Triton Thalassic Technologies, Inc, a company engaged in the non- thermal pathogen inactivation of blood products; photo-activation of therapeutic compounds and the treatment/control of micro-organism contaminated fluids for the industrial, food packaging, healthcare and pharmaceutical industries.

Mr. Ressler is also the founder and Chairman of EP Therapeutics, Inc. a bio-pharmaceutical company engaged in the development of a
new class of therapeutics as safer treatments for human cancers by eliminating the need for chemotherapy or radiation treatment protocols.

From 1975 to December 1993 he served as Chairman and CEO of Universal Voltronics Corporation, a public company (NASDAQ and AMEX) that developed high energy products and systems for scientific research, medical diagnostics/therapies and for industrial applications. In March 1990, UVC became a public subsidiary of Thermo Fisher Scientific.

Mr. Ressler served on the Board of Directors of StemCyte Inc., a company engaged in Umbilical Cord Blood Banking and stem cell therapeutics and also served on the scientific advisory board of the University of Connecticut Biotechnology center.

Mr. Ressler is the inventor of 6 patents in the field of monochromatic UV sterilization of opaque industrial fluids, blood products, injectables, ophthalmic and healthcare packaged products.